All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld Perspectives » What do Macroeconomics, Creativity and Upfront Payments Have in Common?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

What do Macroeconomics, Creativity and Upfront Payments Have in Common?

Aug. 24, 2011
By Trista Morrison
No Comments

What do macroeconomics, creativity and upfront payments have in common? They’re all featured in this week’s issue of BioWorld Insight!

I’m going to put on my long-discarded marketing hat for a minute and say I think we put together a really interesting issue of Insight this week. Of course as the Insight editor, I always think we’ve put together a really interesting issue . . . but just check this out:

  • Our cover story (Macro Woes Could Impact Biotech Financing, M&A) looks at how the S&P downgrade, increased unemployment, decreased consumer spending and other macroeconomic issues could trickle down to biotech. Analysts see haunting similarities between the economy today and at the beginning of the 2008 recession, which could mean challenges for biotech equity and convertible debt financings, lower valuations, more attrition risk, and more opportunistic M&A.
  • Another article (Upfront-Milestone Balance Shifting in Biotechs Favor) highlights Deloitte data showing that upfront payments in biotech licensing deals – which have been shrinking since 2000 – increased in the first half of 2011. On the M&A front, however, CVRs and earn-outs are on the rise.
  • Our third article (New Use for Cash? Amgen Gives NPS Royalty Advance) looks at how economic pressures are stimulating some out-of-the-box biotech solutions, such as Array BioPharma Inc. and Genentech’s clever product-agnostic ChK-1 inhibitor licensing deal, and NPS Pharmaceuticals Inc.’s decision to monetize a royalty stream with partner Amgen Inc. rather than with a traditional private equity group.
  • Plus there’s weekly Insight features including a fundraising chart, breaking news summary, deal-making data and more!
We reprinted this week’s Insight cover story on the economy in Monday’s issue of BioWorld Today, which I’m guessing most readers of this blog subscribe to. But if you missed it, or if you’d like to check out the whole issue of Insight, send me an email at trista.morrison@bioworld.com and I’ll email you a free copy.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing